Top Pharmaceutical Companies in Boston, MA (141)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue has risen at a steady mid- to high-single-digit pace—FY2025 grew 8.3% on a normalized basis, with FY2026 Q1 and Q2 up 7.7% and 7.3% respectively, alongside 3.8% active-customer growth. Management also raised its FY2026 net sales outlook, pointing to continued expansion.
Customer Loyalty & Retention: Autoship sales increased 9.3% in Q2 FY2026 to about $2.82 billion and represented 84.6% of total sales, supporting predictable, repeat purchasing. Sales per active customer also edged up to $602, indicating deepening engagement.
Profitability: Adjusted EBITDA climbed 23.7% in Q2 FY2026 to $226.7 million with a 6.8% margin, and net income rose year over year. These gains indicate improving operating earnings alongside growth.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.
Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.
Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.
We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically...
Precision Medicine Group's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue in the Precision Medicine business is described as rising year over year in 2026 with sequential gains, indicating ongoing momentum. This is accompanied by scaling of integrated services across clinical research, laboratories, and commercialization.
Market Expansion: The company expanded its geographic footprint by opening a Singapore office to grow its Asia-Pacific presence and pursuing hiring across multiple Latin American countries. It reports operations across more than 50 locations spanning North America, Europe, and Asia-Pacific.
Investor Backing & Capital Strength: A definitive agreement for a multibillion-dollar acquisition by McKesson highlights significant scale and strategic value. Growth has also been supported by selective acquisitions and capability additions, such as Redwood Outcomes.
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on...
We are building AI to expand the boundaries of medicine. Our quantum chemistry AI platform, powered by an industry-leading chemoproteomics data generation engine, learns the rules of molecular reactivity making programmable small molecule drug design a reality. With any protein target now within reach, we are generating a pipeline of potential first-in-class candidates, starting with unmet needs in oncology, immunology...
EdenRoc Sciences is a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies. EdenRoc specializes in enabling efficient translation of top tier academic and government science into technologies which provide novel and cutting-edge research tools, diagnostics, and pharmaceuticals.
ProcDNA is a global analytics and technology consulting firm dedicated to delivering exceptional commercial analytics and technology solutions to the life sciences and healthcare sectors. Established in 2020, the company leverages a blend of design thinking, advanced data analytics, and AI to solve complex business challenges, transform data into commercial intelligence, and help pharmaceutical and biotechnology organizations achieve their goals...
Advancing knowledge to improve lives.™ We are a global strategic partner with decades of experience across the entire life sciences product lifecycle. We excel in providing our clients with unique insights and efficiencies to support them in their journey to improve health outcomes and ultimately the quality of people’s lives. By connecting our full suite of products and services from scientific...
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address...
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
EVERSANA is the provider of global services to the life science industry.
EVERSANA's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.
Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.
Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.
We are a biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.
Lyra Therapeutics is a clinical-stage biotechnology company developing long-acting, locally delivered anti-inflammatory implants to treat chronic rhinosinusitis (CRS). The company designs bioabsorbable drug-eluting matrices that release steroid therapy directly to sinonasal tissues for sustained relief, advancing lead candidates (LYR-210 and LYR-220) through late-stage clinical trials and pursuing commercialization and strategic alternatives to benefit CRS patients.
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new...
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused...
Vertex Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials depict Vertex as a leader with near‑dominance in cystic fibrosis and first‑mover approvals in CRISPR‑based gene editing. This is supported by broad real‑world CF impact and landmark authorizations for Casgevy.
Strong Revenue Growth: Reported year‑over‑year revenue growth in 2025 and raised guidance for 2026 indicate ongoing momentum. Quarterly performance aligned with or exceeded guidance during the year, underscoring execution against growth plans.
Diversified Revenue Streams: Early contributions in 2025 from Alyftrek, Journavx, and Casgevy, with management signaling higher non‑CF revenues in 2026, show a broadening base beyond CF. Guidance highlighting non‑CF contribution points to increasing mix diversification over the near term.
Solid Biosciences is a precision genetic medicine company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and genetic cardiomyopathies. The company also develops genetic regulators and other enabling technologies intended to improve gene-therapy delivery. Founded by people directly affected by Duchenne, its mission is...





































